Biodegradable polymer drug-eluting stents versus durable polymer drug-eluting stents for percutaneous coronary intervention: a contemporary registry-based analysis.
Journal
Coronary artery disease
ISSN: 1473-5830
Titre abrégé: Coron Artery Dis
Pays: England
ID NLM: 9011445
Informations de publication
Date de publication:
01 03 2022
01 03 2022
Historique:
pubmed:
3
6
2021
medline:
8
3
2022
entrez:
2
6
2021
Statut:
ppublish
Résumé
We aimed to compare the long-term outcomes of patients undergoing percutaneous coronary intervention (PCI) with biodegradable polymer drug-eluting stents (BP-DES) versus durable polymer drug-eluting stents (DP-DES). Among 11 517 PCIs with second-generation DES performed in our institution between 2007 and 2019, we identified 8042 procedures performed using DP-DES and 3475 using BP-DES. The primary outcome was target lesion failure, the composite target lesion revascularization (TLR), target vessel myocardial infarction and death. Propensity score matching was used to create a well-balanced cohort. Mean follow-up was 4.8 years. Of the 3413 matched pairs, 21% were females, and the mean age was 66 years. At 1 year, the primary outcome occurred in 8.3% patients versus 7.1% (P = 0.07), and TLR rate was 3% versus 2% (P = 0.006) in patients with DP-DES and BP-DES respectively. Within 5 years, the primary outcome occurred in 23.1% versus 23.4% (P = 0.44), and the rate of TLR was 7.2% versus 6.5% (P = 0.07) in patients with DP-DES and BP-DES, respectively. Similar rates of the composite outcome were observed throughout the entire follow-up. Target lesion revascularization rates were lower in the BP-DES group at 1-year but equalized within 5 years.
Identifiants
pubmed: 34074911
doi: 10.1097/MCA.0000000000001066
pii: 00019501-202203000-00006
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105-113Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Nowbar AN, Gitto M, Howard JP, Francis DP, Al-Lamee R. Mortality from Ischemic Heart Disease. Circ Cardiovasc Qual Outcomes 2019; 12:e005375.
Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al.; ESC Scientific Document Group. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019; 40:87–165.
Heart. Biodegradable-polymer drug-eluting stents: back to the future? 2017. https://heart-bmj-com.beilinson-ez.medlcp.tau.ac.il/content/103/2/91 . [Accessed 27 November 2020].
Nakazawa G, Finn AV, Vorpahl M, Ladich ER, Kolodgie FD, Virmani R. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. J Am Coll Cardiol 2011; 57:390–398.
Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011; 57:1314–1322.
Garg S, Serruys PW. Coronary stents: looking forward. J Am Coll Cardiol 2010; 56:S43–S78.
Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011; 378:1940–1948.
Yamaji K, Räber L, Zanchin T, Spitzer E, Zanchin C, Pilgrim T, et al. Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial. Eur Heart J 2016; 37:3386–3395.
Adriaenssens T, Joner M, Godschalk TC, Malik N, Alfonso F, Xhepa E, et al.; Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort (PRESTIGE) Investigators. Optical coherence tomography findings in patients with coronary stent thrombosis: a report of the PRESTIGE Consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort). Circulation 2017; 136:1007–1021.
Otsuka F, Byrne RA, Yahagi K, Mori H, Ladich E, Fowler DR, et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J 2015; 36:2147–2159.
Windecker S, Haude M, Neumann FJ, Stangl K, Witzenbichler B, Slagboom T, et al. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial. Circ Cardiovasc Interv 2015; 8:e001441.
Otsuka F, Cheng Q, Yahagi K, Acampado E, Sheehy A, Yazdani SK, et al. Acute thrombogenicity of a durable polymer everolimus-eluting stent relative to contemporary drug-eluting stents with biodegradable polymer coatings assessed ex vivo in a swine shunt model. JACC Cardiovasc Interv 2015; 8:1248–1260.
Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, et al. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. JACC Cardiovasc Interv 2013; 6:777–789.
Zanchin C, Ueki Y, Zanchin T, Häner J, Otsuka T, Stortecky S, et al. Everolimus-eluting biodegradable polymer versus everolimus-eluting durable polymer stent for coronary revascularization in routine clinical practice. JACC Cardiovasc Interv 2019; 12:1665–1675.
Kandzari DE, Koolen JJ, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, et al.; BIOFLOW V Investigators. Ultrathin bioresorbable-polymer sirolimus-eluting stents versus thin durable-polymer everolimus-eluting stents for coronary revascularization: 3-year outcomes from the Randomized BIOFLOW V Trial. JACC Cardiovasc Interv 2020; 13:1343–1353.
Monjur MR, Said CF, Bamford P, Parkinson M, Szirt R, Ford T. Ultrathin-strut biodegradable polymer versus durable polymer drug-eluting stents: a meta-analysis. Open Heart 2020; 7:e001394.
El-Hayek G, Bangalore S, Casso Dominguez A, Devireddy C, Jaber W, Kumar G, et al. Meta-analysis of randomized clinical trials comparing biodegradable polymer drug-eluting stent to second-generation durable polymer drug-eluting stents. JACC Cardiovasc Interv 2017; 10:462–473.
Lou Y, Yu Y, Xi Z, Gao Y, Liu W, Nie X. Five-year outcomes of biodegradable polymer drug-eluting stents versus second-generation durable polymer drug-eluting stents: a meta-analysis of randomized controlled trials. Cardiovasc Drugs Ther 2019; 33:557–566.
Iglesias JF, Muller O, Heg D, Roffi M, Kurz DJ, Moarof I, et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet 2019; 394:1243–1253.
Choe JC, Cha KS, Lee JG, Kim J, Shin JY, Ahn J, et al.; Korea Acute Myocardial Infarction Registry-National Institutes of Health Investigators. Long-term outcomes of biodegradable versus second-generation durable polymer drug-eluting stent implantations for myocardial infarction. JACC Cardiovasc Interv 2020; 13:97–111.